Inhibition of kynurenine 3‐monooxygenase (KMO) reduces fentanyl and sucrose intake and relapse‐like behaviour in rats
British Journal of Pharmacology · 2026-09 · 183 (18) · 5458-5475
DOI: 10.1111/bph.70549 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 23.06.2026. Verfasst von Carlos Núñez-de la Calle und 12 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad Complutense, Madrid, Spain. Hauptthemen laut MEDLINE: Kynurenine 3-Monooxygenase, Sucrose, Fentanyl, Behavior, Animal. Die Arbeit nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Brain Foundation, Ministerio de Ciencia e Innovación, Swedish Research Council.
Abstract (Originalsprache)
Background and Purpose Opioid use disorder, particularly involving fentanyl, poses major challenges due to high relapse rates and limited effectiveness of pharmacotherapies. The kynurenine pathway has emerged as a target for addiction treatment through its modulation of glutamatergic and dopaminergic neurotransmission. This study investigates the effects of kynurenine 3‐monooxygenase (KMO) inhibition on fentanyl self‐administration in rats. Experimental Approach Adult male rats received the KMO inhibitor, Ro 61‐8048 during fentanyl self‐administration. Responding was assessed across acquisition, maintenance, extinction and reinstatement. The involvement of nicotinic acetylcholine receptor α7 subunit ( α 7nAChR) was investigated using the positive allosteric modulator PNU‐120596. Sucrose self‐administration, locomotor activity and rotarod performance were also evaluated. Kynurenine pathway metabolites were quantified in plasma and nucleus accumbens using ultra‐performance liquid chromatography‐mass spectrometry. Key Results Ro 61‐8048 reduced fentanyl intake and active lever responding across all addiction phases. These effects were associated with increased kynurenic acid (KYNA) levels and altered kynurenine pathway metabolite profiles. PNU‐120596 did not prevent Ro 61‐8048 effects, indicating an α 7nAChR‐independent mechanism. Although Ro 61‐8048 reduced sucrose self‐administration and spontaneous locomotor activity, it did not affect rotarod performance, progressive ratio breakpoints nor did it produce aversive behaviour suggesting that KMO inhibition modulates the reinforcing strength of both drug and natural rewards, rather than inducing general behavioural suppression. Conclusion and Implications KMO inhibition with Ro 61‐8048 robustly attenuates fentanyl‐directed behaviour and affects kynurenine pathway metabolism beyond a shift towards KYNA production. These findings support KMO inhibition as a potential therapeutic strategy for opioid use disorder and warrant further investigation into its underlying mechanisms and translational potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad Complutense, Madrid, Spain.
- Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
- Red de Investigación en Atención Primaria en Adicciones (RIAPAd), ISCIII, Madrid, Spain.
- Instituto Universitario de Investigación en Neuroquímica (IUIN), Facultad de Medicina, Universidad Complutense, Madrid, Spain.
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), ISCIII, Madrid, Spain.
- Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Förderung
- Swedish Brain Foundation
- Ministerio de Ciencia e Innovación
- Swedish Research Council
- Ministerio de Sanidad
- Instituto de Salud Carlos III
- Vetenskapsrådet
- Ministerio de Sanidad, Servicios Sociales e Igualdad
Zitieren
APA
Núñez-de la Calle, C., Careaga, L., Malan-Müller, S., Del Río-García, Á., Trueba, Y., Gil de Biedma-Elduayen, L., Morales-Puerto, N., Vidal, R., Wiman, Å., Erhardt, S., Gutiérrez-López, M. D., O'Shea, E., & Colado, M. I. (2026). Inhibition of kynurenine 3‐monooxygenase (KMO) reduces fentanyl and sucrose intake and relapse‐like behaviour in rats. British Journal of Pharmacology, 183(18), 5458-5475. https://doi.org/10.1111/bph.70549
Vancouver
Núñez-de la Calle C, Careaga L, Malan-Müller S, Del Río-García Á, Trueba Y, Gil de Biedma-Elduayen L, et al. Inhibition of kynurenine 3‐monooxygenase (KMO) reduces fentanyl and sucrose intake and relapse‐like behaviour in rats. British Journal of Pharmacology. 2026;183(18):5458-5475. doi:10.1111/bph.70549
BibTeX
@article{NezdelaCalle2026,
author = {Núñez-de la Calle, Carlos and Careaga, Lluna and Malan-Müller, Stefanie and Del Río-García, Álvaro and Trueba, Yaiza and Gil de Biedma-Elduayen, Leticia and Morales-Puerto, Nuria and Vidal, Rebeca and Wiman, Åsa and Erhardt, Sophie and Gutiérrez-López, María Dolores and O'Shea, Esther and Colado, María Isabel},
title = {Inhibition of kynurenine 3‐monooxygenase (KMO) reduces fentanyl and sucrose intake and relapse‐like behaviour in rats},
journal = {British Journal of Pharmacology},
year = {2026},
volume = {183},
number = {18},
pages = {5458--5475},
doi = {10.1111/bph.70549}
}
EUVIMED